Anguilla japonica chemotactic factor CXCLF2 recombinant protein as well as coding gene and application thereof

By screening expression vectors and strains, the expression amount of Japanese eel chemokine CXCL_F2 was increased, and its expression and purification problems were solved, and biologically active recombinant protein was obtained, which realized its potential application as an anti-inflammatory drug and immune adjuvant, and solved the problem of The problem of difficult expression and purification of chemokine proteins in the prior art.

CN118909076APending Publication Date: 2024-11-08JIMEI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410913742.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, there are difficulties in the expression and purification of chemokine proteins, and there has been no research and biological activity of this chemokine in Japanese eels, which limits its application as an anti-inflammatory drug or immune adjuvant.

Method used

By screening suitable expression vectors and strains, the expression of the Japanese eel chemokine CXCL_F2 is increased, and the amino acid and coding gene sequence of its recombinant protein are provided. The pGEX-6P-1 vector and E. coli Rostta (DE3) strain are used for expression. The expression and purification problems were solved and their immune response and chemotaxis activities were explored.

Benefits of technology

The soluble and biologically active CXCL_F2 recombinant protein has the potential to inhibit inflammatory response. It has application value as an anti-inflammatory drug and immune adjuvant, is non-cytotoxic, is easy to operate, and has a high purification rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909076A_ABST
    Figure CN118909076A_ABST
Patent Text Reader

Abstract

The invention relates to a Japanese eel chemotactic factor CXCLF2 recombinant protein as well as a coding gene and application thereof. The Japanese eel chemotactic factor CXCLF2 recombinant protein has biological activity, can inhibit the occurrence of inflammatory reaction, has no cytotoxicity, and can be used for preparing anti-inflammatory drugs or immunologic adjuvants. The invention also relates to a gene for coding the Japanese eel chemotactic factor CXCLF2 recombinant protein, and a recombinant expression vector, a cell line, engineering bacteria or host bacteria thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a Japanese eel chemokine CXCL_F2 recombinant protein and a coding gene and application thereof. Background Art

[0002] Inflammation is a defensive response of the body to stimulation, manifested as redness, swelling, heat, pain and dysfunction. Some inflammations are beneficial and belong to the host's autonomous defense response, but some inflammations are harmful and cause attacks on the host's own tissues. At present, for the treatment of inflammation, commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs), steroids and biological agents. NSAIDs can reduce the inflammatory response by inhibiting the synthesis and release of inflammatory mediators. Common NSAIDs include ibuprofen, aspirin, etc. Steroids can reduce the inflammatory response by inhibiting immune mediators. Commonly used steroid drugs include prednisone, hydrocortisone, etc. Biological agents are drugs for targeted therapy of specific inflammatory mediators or cells, such as anti-tumor necrosis factor (TNF) biological agents such as infliximab. However, although these drugs are very effective in certain specific cases, they still have problems such as weak specificity and serious side effects after long-term use.

[0003] With the discovery of chemokines, anti-inflammatory drug design has a more attractive new target. Studies have found that chemokines are a class of small cytokines or signaling proteins secreted by cells that control the movement and activation of immune cells. As key regulators of immune responses, they are a bridge between innate immune responses and adaptive immune responses. The main function of chemokines is to induce directional cell migration, recruit and activate white blood cells to act on the site of infection to participate in immune responses. Chemokines mediate immune responses in two ways: the first is that chemokines can directly act on white blood cells to induce them to express integrins, release cytokines, and induce endothelial cell factors to express adhesion molecules, recruit more inflammatory cells to pass through the blood vessel wall, and gather at the site of inflammation. The second is that chemokines and other factors indirectly induce glial cells, macrophages, vascular endothelial cells, smooth muscle cells, etc. to produce various chemokines, thereby generating a cascade reaction to expand the inflammatory response and recruit more inflammatory cells to concentrate at the site of lesions. At the same time, chemokines can bind to G protein-coupled receptors and have been proven to be the target of new drug development. They have potential application value as inflammatory treatment drugs and immune adjuvants.

[0004] In mammals, chemokines are divided into four different subfamilies according to the relative positions of the two conserved cysteine ​​residues at the N-terminus: CC, CXC, CX3C, and XC. C represents cysteine, and X represents amino acid residues other than cysteine. Some fish-specific chemokines have been found in bony fish and named CXCL_F1-5 (CXC Chemokineligands fish specific clade, CXCL_F). In aquatic animals, chemokine CXCL_F2 has been shown to be involved in the innate and adaptive immune responses of some bony fish. In the banded rock sea bream (Oplegnathus fasciatus), the expression of CXCL-F2 was upregulated after peripheral blood lymphocytes (PBLs) were stimulated with lipopolysaccharide (LPS) and polyinosinic-polycytidylic acid (Poly I:C); after the banded rock sea bream was infected with Edwardsiella tarda, Streptococcus iniae and Red sea bream iridovirus (RSIV), the expression of CXCL-F2 in the gills, spleen, liver and kidney tissues was upregulated; at the same time, the study found that recombinant CXCL-F2 protein can promote the proliferation and migration of leukocytes in the head kidney of banded rock sea bream. In the early stages of viral haemorrhagic septicaemia (VHS) and enteric redmouth disease (ERM) in trout (Salmo trutta), CXCL-F2 expression was significantly upregulated. In the eel (Monopterus albus), there are two CXCL-F2 isoforms (CXCL-F2a and CXCL-F2b). After Aeromonas veronii infection of the eel, CXCL-F2a was not significantly upregulated in any tissue. After Poly I∶C treatment, CXCL-F2a was not significantly upregulated in any tissue, while CXCL-F2b was significantly upregulated in the spleen, liver, intestine and kidney. After immunizing large yellow croaker (Larimichthyscrocea) with inactivated bacterial vaccine, CXCL-F2 was upregulated in the spleen and head kidney, the immune tissues of large yellow croaker. Chemotactic activity detection using CXCL-F2 recombinant protein revealed that it could recruit monocytes, lymphocytes and eosinophils.This indicates that chemokine CXCL_F2 can respond to different immunogen stimuli, recruit immune cells to the site of infection to eliminate pathogens, eliminate inflammation, and maintain the body's balance.

[0005] However, chemokine proteins contain transmembrane domains and have a small molecular weight, which poses certain difficulties in prokaryotic expression and protein purification. Summary of the invention

[0006] The purpose of the present invention is to overcome the deficiencies of the prior art, and to provide a Japanese eel chemokine CXCL_F2 gene, protein and application thereof, which solve the problems in the above-mentioned background technology. The present invention screens the expression vector and expression strain of the chemokine CXCL_F2, solves the problems of its difficult expression and purification, and further improves its expression level. At the same time, there has been no research on the chemokine in Japanese eels, and there has been no report on its biological activity. The inventor not only proposed a feasible method to obtain in vitro soluble protein, but also further studied the in vitro immune response and in vitro chemotactic activity of the chemokine CXCL_F2, and explored whether it has application and promotion value as an anti-inflammatory drug and immune adjuvant, laying the foundation for the immune prevention and treatment of Japanese eel diseases.

[0007] One of the technical solutions adopted by the present invention to solve the technical problem is: to provide a Japanese eel chemokine CXCL_F2 protein, whose amino acid sequence is shown in SEQ ID NO:2.

[0008] SEQ ID NO: 2 is as follows:

[0009] MITRVLLVIALLGCLALAQNDFRRNCVCRRTRAGFGDPQNIQDIQIHPPS NTCDKMEIVVTNKNGEQYCLDPKVKKVQELIRRLQGE

[0010] The second technical solution adopted by the present invention to solve its technical problem is: to provide a gene encoding the above-mentioned Japanese eel chemokine CXCL_F2 protein, whose nucleotide sequence is shown in SEQ ID NO: 1.

[0011] SEQ ID NO: 1 is as follows:

[0012] ATGATCACCAGAGTCCTCCTAGTCATCGCCCTCCTCGGCTGCCTGGCACTTGCACAGAATGATTTCAGGAGAAACTGCGTGTGTCGCCGTACCCGCGCAGGATTCGGGGACCCCCAAAACATCCAGGACATC CAGATCCACCCCCCTTCCAACACCTGTGATAAAATGGAGATTGTTGTTACCAACAAAAATGGGGAGCAGTACTGCTTGGATCCGAAAGTGAAGAAGGTCCAGGAGCTGATTAGGCGCCTGCAGGGCGAGTAA

[0013] A recombinant expression vector, cell line, engineered bacteria or host bacteria comprising the above gene.

[0014] Preferably, the recombinant expression vector is pGEX-6P-1.

[0015] Preferably, the cell line is Rostta (DE3).

[0016] Preferably, the engineered bacteria is Escherichia coli.

[0017] The use of the above-mentioned Japanese eel chemokine CXCL_F2 protein in the preparation of anti-inflammatory drugs or immune adjuvants.

[0018] The implementation of the present invention has the following beneficial effects:

[0019] The present invention provides a prokaryotic expression vector and a prokaryotic expression strain that can obtain a soluble Japanese eel chemokine CXCL_F2 recombinant protein, the recombinant protein has biological activity, can inhibit the occurrence of inflammatory reactions, and has the potential to be used as an anti-inflammatory drug; the recombinant protein has no cytotoxicity and can be used to prepare an additive for disease prevention and treatment. The protein purification method provided by the present invention is simple to operate and has a high protein yield. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a diagram of the induced expression of the Japanese eel chemokine CXCL_F2 recombinant protein.

[0021] IPTG: isopropyl-β-D-thiogalactoside;

[0022] M:Marker.

[0023] Lanes 1 to 2: proteins expressed by the strain containing pGEX-6P-1 without induction and after IPTG induction;

[0024] Lanes 3-4: proteins expressed by the strain containing pGEX-6P-1-CXCL_F2 without induction and after IPTG induction.

[0025] Figure 2 This is a diagram showing the expression form identification of the Japanese eel chemokine CXCL_F2 recombinant protein.

[0026] M:Marker.

[0027] Lanes 1 to 2: proteins contained in the supernatant and precipitate separated by ultrasonication after IPTG induction of the strain containing pGEX-6P-1;

[0028] Lanes 3-4: proteins contained in the supernatant and precipitate of the strain containing pGEX-6P-1-CXCL_F2 after IPTG induction and ultrasonic separation.

[0029] Figure 3 This is a diagram of the separation and purification of the recombinant protein of Japanese eel chemokine CXCL_F2.

[0030] M:Marker.

[0031] Lanes 1 to 2: supernatant and purified protein isolated by ultrasonication after IPTG induction of the strain containing pGEX-6P-1;

[0032] Lanes 3-4: Supernatant and purified protein from the strain containing pGEX-6P-1-CXCL_F2 after IPTG induction and ultrasonic separation.

[0033] Figure 4 This is a diagram showing the cytotoxicity analysis of the recombinant protein of Japanese eel chemokine CXCL_F2.

[0034] Figure 5 This is a graph analyzing the chemotactic activity of the Japanese eel chemokine CXCL_F2 recombinant protein on leukocytes.

[0035] Figure 6 This is an analysis diagram of the effect of Japanese eel chemokine CXCL_F2 recombinant protein on cellular NO release. DETAILED DESCRIPTION

[0036] In order to better understand the present invention, the present invention is further described in detail below in conjunction with the embodiments and drawings. However, those skilled in the art understand that the following embodiments are not limitations on the scope of protection of the present invention, and any changes and modifications made on the basis of the present invention are within the scope of protection of the present invention.

[0037] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0038] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0039] Example 1 Cloning and sequence analysis of the Japanese eel chemokine CXCL_F2 gene The inventors first compared the reported fish-specific chemokine sequences in the NCBI database (GCA_025169545.1) and obtained the full-length cDNA sequence of the Japanese eel gene.

[0040] Trizol method for RNA extraction: 100 mg of tissue was taken and 1 mL Place the sample in a centrifuge tube containing Trizol reagent and grind it with a high-throughput tissue grinder, then let it stand for 2 minutes; take 200 μL of tissue homogenate into a new EP tube, add 800 μL of Trizol, and centrifuge at 4°C, 12000 rpm for 10 minutes; take 800 μL of supernatant into a new EP tube, add 160 μL of chloroform, shake for 15 seconds, let it stand for 3 minutes, and centrifuge at 4°C, 12000 rpm for 10 minutes; take the supernatant into a new EP tube, add an equal volume of isopropanol to mix, let it stand at room temperature for 10 minutes, centrifuge at 4°C, 12000 rpm for 10 minutes, and discard the supernatant; add 1 mL of pre-cooled 80% anhydrous ethanol to wash the precipitate, centrifuge at 4°C, 12000 rpm for 10 minutes, and discard the supernatant; then wash the precipitate with 75% anhydrous ethanol, and discard the supernatant; centrifuge for 5 minutes, aspirate the residual liquid, open the lid and keep it ventilated, and let it stand for 5 minutes; add 30 μL RNase-free Dissolve in water, detect RNA concentration, purity and integrity by spectrophotometer, and store at -80℃ for future use.

[0041] cDNA synthesis: The extracted RNA was reverse transcribed into cDNA according to the instructions of AG11615 Evo M-MLV Plus cDNA Kit and the synthesized cDNA was stored at -20℃.

[0042] PCR amplification: According to the results of sequence analysis, amplification primers were designed with a fragment length of 358 bp, covering the coding region sequence. The primer sequences are as follows:

[0043] Primer Name Primer Sequence (5'-3')

[0044] AjCXCL_F2-F ATGATCACCAGAGTCCTCCTAGT (shown in SEQ ID NO: 4)

[0045] AjCXCL_F2-R TTACTCGCCCTGCAGGCGCCTAA (as shown in SEQ ID NO: 5)

[0046] The PCR reaction components are as follows: 2×GoTaq Green Master Mix, 25 μL; Nuclease-free Water, 18 μL; Primer F / R, 2.5 μL; cDNA, 2 μL. PCR instrument reaction program: 95°C, 3 min; 95°C, 30 s, Tm, 30 s, 72°C, 30 s, 35 cycles; 72°C, 7 min; stored at 4°C for future use.

[0047] The PCR product was recovered, connected, transformed, and the positive clone was sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing and compared with the Japanese eel genome sequence in the NCBI database. The CDS region of the gene is 264 bp (as shown in SEQ ID NO: 1), and the open reading frame of the gene encodes a protein of 87 amino acids (as shown in SEQ ID NO: 2).

[0048] SEQ ID NO: 1 is as follows:

[0049] ATGATCACCAGAGTCCTCCTAGTCATCGCCCTCCTCGGCTGCCTGGCACTTGCACAGAATGATTTCAGGAGAAACTGCGTGTGTCGCCGTACCCGCGCAGGATTCGGGGACCCCCAAAACATCCAGGACATC CAGATCCACCCCCCTTCCAACACCTGTGATAAAATGGAGATTGTTGTTACCAACAAAAATGGGGAGCAGTACTGCTTGGATCCGAAAGTGAAGAAGGTCCAGGAGCTGATTAGGCGCCTGCAGGGCGAGTAA

[0050] SEQ ID NO: 2 is as follows:

[0051] MITRVLLVIALLGCLALAQNDFRRNCVCRRTRAGFGDPQNIQDIQIHPPS NTCDKMEIVVTNKNGEQYCLDPKVKKVQELIRRLQGE

[0052] Example 2 In vitro recombinant expression of Japanese eel chemokine CXCL_F2

[0053] Construction of recombinant expression strain: The amino acid sequence of the target protein was analyzed, and the signal peptide and mature peptide were predicted using SignalP-6.0 (https: / / services.healthtech.dtu.dk / service.php?SignalP), and the mature peptide sequence was cloned into the expression vector pGEX-6P-1 and named pGEX-6P-1-CXCL_F2 (such as SEQ ID NO: 3).

[0054] SEQ ID NO: 3 is as follows:

[0055] ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTGGGATCCCCGGAATTCCAGAATGATTTCAGGAGAAACTGCGTGTGTCGCCGTACCCGCGCAGGATTCGGGGACCCCCAAAACATCCAGGACATCCAGATCCACCCCCCTTCCAACACCTGTGATAAAATGGAGATTGTTGTTACCAACAAAAATGGGGAGCAGTACTGCTTGGATCCGAAAGTGAAGAAGGTCCAGGAGCTGATTAGGCGCCTGCAGGGCGAGTAA

[0056] The primer sequences are as follows:

[0057] Primer name Primer sequence (5'-3')

[0058] AjCXCL_F2Q-gstEcoRI-F: CCGGAATTCCAGAATGATTTCAGGA (as shown in SEQ ID NO: 6)

[0059] AjCXCL_F2Q-gstXhoI-R: CCGCTCGAGTTACTCGCCCTGCAGG (as shown in SEQ ID NO: 7)

[0060] Note: AjCXCL_F2Q indicates the removal of the signal peptide sequence, and gst indicates the tag carried by the vector.

[0061] The successfully constructed expression vector was transformed into expression competent cells BL21 (DE3), Rostta (DE3), and Rosttagami2 (DE3).

[0062] Induced expression of recombinant proteins and analysis of expression products: Single clones of AjCXCL_F2-BL21(DE3), AjCXCL_F2-Rostta(DE3), and AjCXCL_F2-Rostta gami2(DE3) strains were inoculated into 10 mL of LB liquid medium containing corresponding antibiotics and cultured at 37°C and 220 rpm until OD 600 0.4-0.6; add IPTG at a final concentration of 1mM, induce at 28℃, 180rpm for 16h; take 1mL of the induced expression bacterial solution, the uninduced bacterial solution, and the control group empty vector induced expression bacterial solution, and the control group empty vector uninduced bacterial solution for SDS-PAGE electrophoresis detection. The results showed that the AjCXCL_F2-Rostta (DE3) expression strain had differentially expressed protein bands between 25KD and 35KD ( Figure 1 ). However, no differentially expressed protein bands appeared in the expression strains AjCXCL_F2-BL21(DE3) and AjCXCL_F2-Rostta gami2(DE3).

[0063] The bacterial liquid after induced expression of AjCXCL_F2-Rostta (DE3) strain, the bacterial liquid after uninduced expression, the bacterial liquid after induced expression of empty vector in the control group, and the bacterial liquid without induction in the control group were centrifuged at 4℃ and 8000rpm for 5min to collect the bacteria, and 1mL of lysis buffer was added, and ultrasonic disruption was carried out in an ice water bath for 10min, with the conditions of ultrasonic disruption for 9s and pause for 6s; centrifuged at 4℃ and 12000rpm for 10min to separate the bacterial supernatant and bacterial precipitate, and an equal volume of 2×SDS loading buffer was added, and boiled at 95℃ for 7min; SDS-PAGE electrophoresis was used to detect the expression form of recombinant protein. The results showed that the protein content in the supernatant of the disrupted bacterial liquid was significantly higher than that in the bacterial precipitate, and the chemokine CXCL_F2 mainly existed in the form of soluble protein ( Figure 2 ).

[0064] Example 3 Purification of Japanese eel chemokine CXCL_F2 recombinant protein

[0065] Induce the expression of Japanese eel chemokine CXCL_F2 recombinant protein in large quantities: Inoculate a single clone of the AjCXCL_F2-Rostta (DE3) strain into 200 mL of LB liquid medium containing ampicillin and chloramphenicol, and expand the culture at 37°C and 220 rpm until the OD 600 The cell culture medium was 0.4-0.6; IPTG was added at a final concentration of 1 mM, and the mixture was induced at 180 rpm for 16 h at 28 ° C; the cells were collected by centrifugation at 8000 rpm for 5 min, 40 mL of PBS was added to resuspend the cells, and the cells were collected by centrifugation at 8000 rpm for 5 min; 40 mL of lysis buffer (PBS containing 0.2% Triton X-100) was added, and the cells were ultrasonically disrupted in an ice-water bath for 20 min, with the conditions of ultrasonication for 9 s and pause for 6 s; the cells were centrifuged at 8000 rpm for 10 min at 4 ° C to separate the supernatant and the precipitate, and the supernatant was retained for later use.

[0066] Purification and verification of recombinant protein of Japanese eel chemokine CXCL_F2: Use GST-tag Purification Resin to purify the protein, take 1 mL of resin in a 1.5 mL centrifuge tube, centrifuge at 1000 rpm for 5 min, and discard the supernatant; add 1 mL of PBS to wash the resin, centrifuge at 1000 rpm for 5 min, and discard the supernatant; add 1 mL of lysis solution to balance the resin, and discard the supernatant; add 1 mL of lysis solution to resuspend the resin and add it to 40 mL of bacterial supernatant, place it in a 4°C refrigerator, and incubate it on a side-swinging shaker for 16 hours; centrifuge at 4°C, 1000 rpm for 10 min, and discard the bacterial supernatant; add 1 mL of PBS to wash the resin, centrifuge at 1000 rpm for 5 min, and discard PBS; repeat the wash twice; add 1 mL of 10 mM GSH, centrifuge at 1000 rpm for 5 min, collect the eluate, and repeat the elution 5 times; use 12% concentration SDS-PAGE gel electrophoresis to detect the protein size and purity, the results are shown in Figure 3 After the target protein was determined, it was dialyzed with 20 mM potassium phosphate buffer, and the dialyzed protein was quantitatively analyzed using a Bradford protein concentration assay kit (Biyotime Biotech, P0006C).

[0067] Example 4 Cytotoxicity of Japanese eel chemokine CXCL_F2 recombinant protein

[0068] Detection of cytotoxicity of purified Japanese eel chemokine CXCL_F2 recombinant protein: According to the instructions of GLPBIO CellCounting Kit-8 (GK10001), blank wells, control wells and experimental wells were set; Japanese eel kidney cells were inoculated in a 24-well plate and cultured in a 28°C, 5% CO2 incubator for 12 hours; 50 μg / mL of recombinant protein or label protein was added to each experimental well, and the plates were incubated in a 28°C, 5% CO2 incubator for 12 hours; the culture medium in the wells was discarded, the culture medium was re-added, the culture medium was mixed with CCK-8 solution in a ratio of 10:1, and the culture plate was incubated in the incubator for 1 hour; the absorbance at 450 nm was measured using an enzyme reader to calculate the cell survival rate.

[0069] The results show that Figure 4 ), the recombinant protein had no obvious cytotoxicity to Japanese eel kidney cells at a concentration of 50 μg / mL, and the cell viability was greater than 92%.

[0070] Example 5 Analysis of chemotactic activity of Japanese eel chemokine CXCL_F2 recombinant protein

[0071] Percoll density gradient separation method to separate leukocytes: Take 1 mL of healthy eel blood and add an equal volume of RPMI1640 incomplete culture medium (containing sodium heparin) to mix well; add 60% Percoll separation solution and blood-culture medium suspension in a ratio of 2:1 into a centrifuge tube, centrifuge at 24°C, 1000rpm for 30min, discard the upper serum, and carefully aspirate the white blood cell layer; add twice the volume of RPMI 1640 culture medium to mix well, centrifuge at 24°C, 800rpm for 5min to collect cells, and discard the culture medium; add 1 mL of culture medium to resuspend the cells, and count the number of live cells using a cell counter.

[0072] Analysis of the chemotactic activity of the Japanese eel chemokine CXCL_F2 recombinant protein: The chemotactic activity of the recombinant protein was detected using the Transwell assay. The leukocytes were diluted to 1×10 6 cells / mL, 100 μL of leukocytes were added to the upper chamber of the Transwell plate, the recombinant protein and the labeled protein were diluted in RPMI 1640 incomplete medium to a final concentration of 50 μg / mL and 100 μg / mL, respectively, and 600 μL were added to the lower chamber of the Transwell plate; the chemotaxis plate was placed in a 28°C incubator for 3 h, the cells in the lower chamber were collected, the medium was discarded by centrifugation, 300 μL of PBS was added to resuspend the cells, and the cells were counted by flow cytometer.

[0073] The results show that ( Figure 5), the Japanese eel chemokine CXCL_F2 recombinant protein could inhibit (p<0.01) the chemotaxis of leukocytes at 50μg / mL, and the inhibitory effect was more obvious at 100μg / mL.

[0074] Example 6 Effect of Japanese eel chemokine CXCL_F2 recombinant protein on NO release

[0075] According to the instructions of Nanjing Jiancheng Bioengineering Institute's one-step NO detection kit: separate leukocytes, the steps are the same as before; 1×10 7 cells, add recombinant protein and label protein with a final concentration of 50 μg / mL, and incubate the culture plate in an incubator for 3 hours; collect cells, centrifuge at 1000rpm for 5 minutes, discard the supernatant, add 300mL PBS to resuspend the cells; ultrasonically disrupt them in an ice-water bath for 5 minutes to prepare a homogenate; determine the total protein concentration in the homogenate; add the homogenate, reagent 1, and reagent 2 in sequence according to the ratio of 3:2:1, vortex thoroughly to mix, and let stand for 10 minutes; centrifuge at 12000rpm for 10 minutes, and take the supernatant; set blank wells, standard wells, and measurement wells, add double distilled water / 20μmol / L sodium nitrite standard solution / supernatant and color developer to the ELISA plate in a ratio of 2:1, mix well, and let stand for 15 minutes; determine the absorbance of each well at 550nm with an ELISA instrument, and calculate according to the NO content formula.

[0076] The results show that Figure 6 ), Japanese eel chemokine CXCL_F2 recombinant protein can significantly inhibit (p<0.01) the release of NO at a concentration of 50μg / mL. The release of NO is considered to be an important signal for the occurrence of inflammatory response, so it is believed that Japanese eel chemokine CXCL_F2 recombinant protein can inhibit the occurrence of inflammation.

[0077] Although the specific implementation modes of the present invention are described above, those skilled in the art should understand that the specific implementation modes described are only illustrative and are not intended to limit the scope of the present invention. Equivalent modifications and changes made by those skilled in the art in accordance with the spirit of the present invention should be included in the scope of protection of the claims of the present invention.

Claims

1. A Japanese eel chemokine CXCL_F2 recombinant protein, characterized in that: The amino acid sequence of the Japanese eel chemokine CXCL_F2 protein is shown in SEQ ID NO:

2.

2. A gene encoding the Japanese eel chemokine CXCL_F2 recombinant protein according to claim 1, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO:

1.

3. A recombinant expression vector, cell line, engineered bacteria or host bacteria comprising the Japanese eel chemokine CXCL_F2 recombinant protein gene according to claim 2.

4. The recombinant expression vector of the Japanese eel chemokine CXCL_F2 recombinant protein gene according to claim 3, characterized in that: The recombinant expression vector is pGEX-6P-1.

5. The cell line of the Japanese eel chemokine CXCL_F2 recombinant protein gene according to claim 3, characterized in that: The cell line is Rostta (DE3).

6. The engineered bacteria of the Japanese eel chemokine CXCL_F2 recombinant protein gene according to claim 3, characterized in that: The engineered bacteria is Escherichia coli.

7. Use of the Japanese eel chemokine CXCL_F2 recombinant protein as claimed in claim 1 in the preparation of anti-inflammatory drugs or immune adjuvants.